Zimmer Biomet (NYSE:ZBH) Price Target Cut to $90.00 by Analysts at Wells Fargo & Company

Zimmer Biomet (NYSE:ZBH) had its target price trimmed by Wells Fargo & Company from $98.00 to $90.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has an equal weight rating on the medical equipment provider’s stock.

ZBH has been the topic of several other reports. TD Cowen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. William Blair assumed coverage on Zimmer Biomet in a research report on Friday, February 20th. They set a “market perform” rating on the stock. Sanford C. Bernstein increased their price target on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Finally, Leerink Partners assumed coverage on Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $102.43.

Zimmer Biomet Price Performance

NYSE ZBH opened at $80.31 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The stock’s fifty day moving average price is $92.87 and its 200 day moving average price is $92.81. Zimmer Biomet has a 1 year low of $79.83 and a 1 year high of $108.29. The company has a market cap of $15.54 billion, a price-to-earnings ratio of 22.69, a PEG ratio of 1.89 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the firm earned $1.81 EPS. The firm’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities research analysts forecast that Zimmer Biomet will post 8.39 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is currently 27.12%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.28% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds have recently modified their holdings of the company. Nicholas Hoffman & Company LLC. boosted its stake in shares of Zimmer Biomet by 16.8% during the 1st quarter. Nicholas Hoffman & Company LLC. now owns 15,434 shares of the medical equipment provider’s stock worth $1,396,000 after acquiring an additional 2,223 shares in the last quarter. Integrated Advisors Network LLC purchased a new stake in shares of Zimmer Biomet during the 1st quarter worth about $205,000. Greatmark Investment Partners Inc. boosted its stake in shares of Zimmer Biomet by 2.5% during the 1st quarter. Greatmark Investment Partners Inc. now owns 20,071 shares of the medical equipment provider’s stock worth $1,815,000 after acquiring an additional 491 shares in the last quarter. Corbyn Investment Management Inc. MD boosted its stake in shares of Zimmer Biomet by 0.5% during the 1st quarter. Corbyn Investment Management Inc. MD now owns 34,050 shares of the medical equipment provider’s stock worth $3,079,000 after acquiring an additional 183 shares in the last quarter. Finally, Wilsey Asset Management Inc. boosted its stake in shares of Zimmer Biomet by 11.7% during the 1st quarter. Wilsey Asset Management Inc. now owns 402,984 shares of the medical equipment provider’s stock worth $36,438,000 after acquiring an additional 42,231 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 results beat and guidance raised — Zimmer Biomet reported adjusted EPS of $2.09 (vs. $1.86 est.), revenue of ~$2.09B (beat) and organic sales growth; the company updated FY2026 adjusted EPS guidance to $8.40–8.55. These operational beats and the guidance raise are supportive for longer‑term fundamentals. PR Newswire: Q1 Results
• Neutral Sentiment: Conference call / transcripts are available and highlight the company’s growth drivers and margin expansion; these give investors more detail on product momentum and the salesforce shift but have not calmed near‑term volatility. Earnings Call Highlights
• Negative Sentiment: Finance leadership turnover — CFO Suketu Upadhyay departed and an interim CFO was named; reports link the exit to a sharp intraday selloff and said the stock plunged to multi‑year lows on the news. Leadership uncertainty in the finance function is a clear near‑term negative. CFO Transition (PR Newswire) Article: Stock Plunges
• Negative Sentiment: Analyst price‑target cuts and mixed ratings — multiple firms trimmed targets (examples: JPMorgan $100→$95, Wells Fargo $98→$90, Stifel $110→$105, Truist trimmed its PT to $92) which lowers street support levels and can amplify selling pressure. Benzinga: Analyst Notes The Fly TickerReport
• Negative Sentiment: Technical / market context — the stock is trading with elevated volume, underperforming peers and around its 52‑week low, increasing the likelihood of momentum-driven downside until leadership/catalysts stabilize. MarketWatch: Underperformance

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.